In 2016, it has been reported that AG-120 displays a 35% clinical benefit rate and a favorable safety profile in phase 1 trial in IDH1-mutant gliomas (ClinicalTrials.gov NCT02073994) [76] (Table 1). The gene discussed is IDH1; the disease is central nervous system cancer.